149 related articles for article (PubMed ID: 11503956)
1. Myelodysplastic syndromes.
Odenike O; Anastasi J; Le Beau MM
Clin Lab Med; 2011 Dec; 31(4):763-84. PubMed ID: 22118747
[TBL] [Abstract][Full Text] [Related]
2. The molecular pathogenesis of myelodysplastic syndromes.
Davids MS; Steensma DP
Cancer Biol Ther; 2010 Aug; 10(4):309-19. PubMed ID: 20592488
[TBL] [Abstract][Full Text] [Related]
3. The Genomics of Myelodysplastic Syndromes: Origins of Disease Evolution, Biological Pathways, and Prognostic Implications.
Awada H; Thapa B; Visconte V
Cells; 2020 Nov; 9(11):. PubMed ID: 33233642
[TBL] [Abstract][Full Text] [Related]
4. The impact of erythroblast enucleation efficiency on the severity of anemia in patients with myelodysplastic syndrome.
An C; Xue F; Sun L; Han H; Zhang Y; Hu Y
Cell Commun Signal; 2023 Nov; 21(1):332. PubMed ID: 37986081
[TBL] [Abstract][Full Text] [Related]
5. Complex karyotype in myelodysplastic syndromes: Diagnostic procedure and prognostic susceptibility.
Shahjahani M; Hadad EH; Azizidoost S; Nezhad KC; Shahrabi S
Oncol Rev; 2019 Jan; 13(1):389. PubMed ID: 30858933
[TBL] [Abstract][Full Text] [Related]
6. Techniques for detecting chromosomal aberrations in myelodysplastic syndromes.
Song Q; Peng M; Chu Y; Huang S
Oncotarget; 2017 Sep; 8(37):62716-62729. PubMed ID: 28977983
[TBL] [Abstract][Full Text] [Related]
7. Combined comparative genomic hybridization and single-nucleotide polymorphism array detects cryptic chromosomal lesions in both myelodysplastic syndromes and cytopenias of undetermined significance.
Evans AG; Ahmad A; Burack WR; Iqbal MA
Mod Pathol; 2016 Oct; 29(10):1183-99. PubMed ID: 27389314
[TBL] [Abstract][Full Text] [Related]
8. Nuclear Nox4-derived reactive oxygen species in myelodysplastic syndromes.
Guida M; Maraldi T; Beretti F; Follo MY; Manzoli L; De Pol A
Biomed Res Int; 2014; 2014():456937. PubMed ID: 24719867
[TBL] [Abstract][Full Text] [Related]
9. Frequency of inherited variants in the MEFV gene in myelodysplastic syndrome and acute myeloid leukemia.
Celik S; Oktenli C; Kilicaslan E; Tangi F; Sayan O; Ozari HO; Ipcioglu O; Sanisoglu YS; Terekeci MH; Erikci AA
Int J Hematol; 2012 Mar; 95(3):285-90. PubMed ID: 22351163
[TBL] [Abstract][Full Text] [Related]
10. Biclonal myelodysplastic syndrome involving six chromosomes and monoallelic loss of RB1 - A rare case.
Al-Achkar W; Wafa A; Klein E; Aljapawe A
Mol Cytogenet; 2011 Aug; 4():16. PubMed ID: 21851601
[TBL] [Abstract][Full Text] [Related]
11. SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes.
Afable MG; Wlodarski M; Makishima H; Shaik M; Sekeres MA; Tiu RV; Kalaycio M; O'Keefe CL; Maciejewski JP
Blood; 2011 Jun; 117(25):6876-84. PubMed ID: 21527527
[TBL] [Abstract][Full Text] [Related]
12. Gene expression patterns in myelodyplasia underline the role of apoptosis and differentiation in disease initiation and progression.
Bar M; Stirewalt D; Pogosova-Agadjanyan E; Wagner V; Gooley T; Abbasi N; Bhatia R; Deeg HJ; Radich J
Transl Oncogenomics; 2008; 3():137-49. PubMed ID: 20396593
[TBL] [Abstract][Full Text] [Related]
13. Whole genome scanning as a cytogenetic tool in hematologic malignancies.
Maciejewski JP; Mufti GJ
Blood; 2008 Aug; 112(4):965-74. PubMed ID: 18505780
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes.
Giagounidis AA; Germing U; Haase S; Aul C
Ther Clin Risk Manag; 2007 Aug; 3(4):553-62. PubMed ID: 18472976
[TBL] [Abstract][Full Text] [Related]
15. Evolving new treatment for myelodysplastic syndromes.
Yoshida Y
Int J Hematol; 2007 Nov; 86(4):297-300. PubMed ID: 18055334
[TBL] [Abstract][Full Text] [Related]
16. Low-level expression of ETV6/TEL in patients with Myelodysplastic syndrome.
Yamagata T; Nakamura Y; Mitani K
Int J Hematol; 2007 Oct; 86(3):282-5. PubMed ID: 17988997
[No Abstract] [Full Text] [Related]
17. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML.
Gondek LP; Tiu R; O'Keefe CL; Sekeres MA; Theil KS; Maciejewski JP
Blood; 2008 Feb; 111(3):1534-42. PubMed ID: 17954704
[TBL] [Abstract][Full Text] [Related]
18. Tyk2 is dispensable for induction of myeloproliferative disease by mutant FLT3.
Nakajima H; Shibata F; Kumagai H; Shimoda K; Kitamura T
Int J Hematol; 2006 Jul; 84(1):54-9. PubMed ID: 16867903
[TBL] [Abstract][Full Text] [Related]
19. Chromosome and molecular abnormalities in myelodysplastic syndromes.
Fenaux P
Int J Hematol; 2001 Jun; 73(4):429-437. PubMed ID: 11503956
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
